(ACET) Adicet Bio - Ratings and Ratios

Adicet Bio, Inc. is a clinical-stage biotechnology company specializing in the development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The companys proprietary platform leverages gamma delta T cells, a unique subset of immune cells with inherent tumor-seeking properties, to engineer chimeric antigen receptor (CAR) T cell therapies. These therapies are designed to enhance persistence and activity in patients, addressing the limitations of traditional autologous CAR T cell therapies. Adicets lead candidate, ADI-001, is an allogeneic gamma delta T cell therapy targeting CD20, currently in Phase I clinical trials for autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkins lymphoma. The company is also advancing ADI-270, an armored gamma delta CAR T cell product candidate targeting CD70, with potential applications in renal cell carcinoma and other CD70+ solid tumor and hematological malignancies. Founded in 2014 and headquartered in Boston, Massachusetts, Adicet Bio is focused on expanding its pipeline to address unmet medical needs in oncology and autoimmune diseases.

Based on the provided and , Adicet Bios stock (NASDAQ:ACET) is currently trading at $0.88 with a 20-day average volume of 1,739,018 shares. The stock is below its 20-day and 50-day simple moving averages (SMA) of $0.93 but remains above its 200-day SMA of $1.24. The Average True Range (ATR) of $0.07 indicates low volatility. From a fundamental perspective, the company has a market capitalization of $71.77 million, with a price-to-book (P/B) ratio of 0.33, suggesting undervaluation relative to its book value. However, the price-to-sales (P/S) ratio of 9.72 reflects a premium valuation relative to its revenue generation. The return on equity (RoE) of -55.73% highlights ongoing losses, typical for early-stage biotechnology companies.